Sue Sisley

Last updated

Suzanne A. Sisley MD is an internist and psychiatrist and former clinical assistant professor at the University of Arizona College of Medicine. She was terminated from her position for her advocacy around ending barriers to schedule 1 drug research.

Contents

Marijuana research and termination

In March 2014, Sisley's proposal to study marijuana use to treat post-traumatic stress disorder (PTSD) was approved by the National Institute on Drug Abuse. [1] After working at the University of Arizona for nearly eight years in various capacities, she was fired from the university in June 2014, ostensibly because of "funding and reorganization issues." Sisley, however, claims the firing was because of her interest in studying the potential medical uses of marijuana to treat PTSD. [2] [3] Sisley has also claimed that the university failed to provide a location for the trial to take place, and that the University of Arizona was "fearful of the word 'marijuana' and [did] not want... their brand aligned with this research." [3] After she was terminated, the university released a statement saying that they had "not received political pressure to terminate any employee as has been suggested in some media and other reports." [3]

“Why was I non-renewed by UA (fired) in 2014?

I want to stress that, much to the displeasure of AZ Legislature back in 2014, medical marijuana was made legal by a vote of the people in 2010.  

And the extreme right-wing politicians still resented it.  They took their frustrations out on my FDA-approved marijuana research project and my employer - the UA.  

The University government relations folks viewed me as a threat to the overall university legislative-approved budget and complained to President Hart.  And the President told the medical school to get rid of me.

The University of Arizona could not take the political heat from those Legislative leaders mentioned in NY TIMES article.  So they fired me. But more importantly, they deserted the veterans/patients who desperately wanted this valuable study in their efforts to cope with PTSD."

-Sue Sisley MD

Sisley was initially focused on nonprofit drug development research into potential medical uses of inhaled marijuana and hoped to seek FDA approval of cannabis for Pain/Exit drug to substitute for opioid dependence. But FDA had been impeding this research which enabled Sisley to begin shifting focus into natural psychedelics such as psilocybin mushrooms. Dr. Sisley is licensed by DEA as schedule 1 manufacturer to farm psilocybin mushroom fruiting bodies to conduct human trials. Sisley was awarded a $2.75 million grant from State of AZ in 2024 to evaluate patients with life-threatening illness using whole psilocybin mushrooms.

This schedule 1 license came after her organization Scottsdale Research Institute toppled over a 53 year old monopoly at University of Mississippi thru a series of petitions in Federal Court, and was among 1st Approved by DEA for Licensing to Grow Cannabis for Research.

Dr. Sisley is currently President of Scottsdale Research Institute [4] & Principal Investigator for FDA-approved randomized controlled trials examining safety/efficacy of smoked marijuana flower for treating pain, post traumatic stress disorder PTSD, and opioid substitution.

Sue is striving to put crucial medically active plants/fungi thru entire FDA drug development process to eventually be available in the market as a safer alternative to synthetic pharmaceuticals. Scottsdale Research Institute in conjunction with their 501(c)(3) Field to Healed Foundation is collecting objective data hoping to urge health insurance companies to pay for whole plant botanical medicines similar to conventional pharmaceuticals.

Research and Ethical Concerns

Dr. Sisley has faced significant scrutiny and controversy regarding her research methodologies and affiliations [5] . Critics have raised concerns about the quality and ethical aspects of her studies. For instance, there have been allegations that some of her research, particularly studies related to cannabis for PTSD, might be influenced by her connections to the cannabis industry. This has led to questions about potential conflicts of interest and the objectivity of her findings​.

Additionally, Sisley's work has sometimes been criticized for lacking rigorous scientific standards. Some researchers argue that her studies do not always adhere to the highest methodological protocols, which could affect the reliability of her results. A particularly serious accusation against Dr. Sisley is that she allegedly manipulated veterans to obscure her role in research controversies. According to reports, veterans involved in her studies were sometimes used to promote her work and defend it against criticism, creating a façade of grassroots support while minimizing her direct involvement. This strategy has been criticized as exploitative, leveraging the credibility and experiences of veterans to shield her research from scrutiny [5] .

Related Research Articles

<span class="mw-page-title-main">Controlled Substances Act</span> United States drug-regulating law

The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs.

John Henry Schwarz is an American theoretical physicist. Along with Yoichiro Nambu, Holger Bech Nielsen, Joël Scherk, Gabriele Veneziano, Michael Green, and Leonard Susskind, he is regarded as one of the founders of string theory.

Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, LSD, and ayahuasca, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.

The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.

<span class="mw-page-title-main">Removal of cannabis from Schedule I of the Controlled Substances Act</span> Proposed changes to the legal status of cannabis in U.S. federal law

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act, the category reserved for drugs that have "no currently accepted medical use", is a proposed legal and administrative change in cannabis-related law at the federal level. After being proposed repeatedly since 1972, in 2024, the US Department of Justice announced it was initiating rulemaking to reschedule cannabis to Schedule III of the Controlled Substances Act.

<span class="mw-page-title-main">National Institute on Drug Abuse</span> Branch of the National Institutes of Health in the United States

The National Institute on Drug Abuse (NIDA) is a United States federal government research institute whose mission is to "advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health."

The Beckley Foundation is a UK-based think tank and UN-accredited NGO, dedicated to activating global drug policy reform and initiating scientific research into psychoactive substances. The foundation is a charitable trust which collaborates with leading scientific and political institutions worldwide to design and develop research and global policy initiatives. It also investigates consciousness and its modulation from a multidisciplinary perspective, working in collaboration with scientists. The foundation is based at Beckley Park near Oxford, United Kingdom. It was founded in 1998, and is directed by Amanda Feilding, Countess of Wemyss.

<span class="mw-page-title-main">Drug policy of California</span> Overview of the drug policy of the U.S. state of California

Drug policy of California refers to the policy on various classes and kinds of drugs in the U.S. state of California. Cannabis possession has been legalized with the Adult Use of Marijuana Act, passed in November 2016, with recreational sales starting January of the next year. With respect to many controlled substances, terms such as illegal and prohibited do not include their authorized possession or sale as laid out by applicable laws.

<span class="mw-page-title-main">Cannabis in the United States</span> Legality, use, culture, market and production of cannabis in the United States

The use, sale, and possession of cannabis containing over 0.3% THC by dry weight in the United States, despite laws in many states permitting it under various circumstances, is illegal under federal law. As a Schedule I drug under the federal Controlled Substances Act (CSA) of 1970, cannabis containing over 0.3% THC by dry weight is considered to have "no accepted medical use" and a high potential for abuse and physical or psychological dependence. Cannabis use is illegal for any reason, with the exception of FDA-approved research programs. However, individual states have enacted legislation permitting exemptions for various uses, including medical, industrial, and recreational use.

<span class="mw-page-title-main">Medical cannabis in the United States</span> Use of cannabis for medical purposes in the United States

In the United States, the use of cannabis for medical purposes is legal in 38 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of March 2023. Ten other states have more restrictive laws limiting THC content, for the purpose of allowing access to products that are rich in cannabidiol (CBD), a non-psychoactive component of cannabis. There is significant variation in medical cannabis laws from state to state, including how it is produced and distributed, how it can be consumed, and what medical conditions it can be used for.

<span class="mw-page-title-main">Drugs in the United States</span>

In the United States, the Federal Food, Drug, and Cosmetic Act defined the word "drug" as an "article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals" and those "(other than food) intended to affect the structure or any function of the body of man or other animals." Consistent with that definition, the U.S. separately defines narcotic drugs and controlled substances, which may include non-drugs, and explicitly excludes tobacco, caffeine and alcoholic beverages.

<span class="mw-page-title-main">2014 Florida Amendment 2</span> Referendum

Florida Amendment 2, Use of Marijuana for Certain Medical Conditions, is an initiative that appeared on the November 4, 2014, ballot in the state of Florida as a citizen initiated state constitutional amendment.

<span class="mw-page-title-main">Cannabis in Montana</span> Legality, use and culture of cannabis in the U.S. state of Montana

In the US state of Montana, cannabis has been legal for both medical and recreational use since January 1, 2021, when Initiative 190 went into effect. Prior to the November 2020 initiative, marijuana was illegal for recreational use starting in 1929. Medical cannabis was legalized by ballot initiative in 2004. The Montana Legislature passed a repeal to tighten Montana Medical Marijuana (MMJ) laws which were never approved by the governor. However, with the new provisions, providers could not service more than three patients. In November 2016 Bill I-182 was passed, revising the 2004 law and allowing providers to service more than three patients. In May 2023, numerous further bills on cannabis legalization and other related purposes passed the Montana Legislature. The Governor of Montana is yet to either sign or veto the bill.

<span class="mw-page-title-main">Cannabis in Israel</span>


The possession, use, and distribution of cannabis without a license in the State of Israel are violations under the Dangerous Drugs Ordinance. A decade ago, despite these regulations, enforcement was relatively lax, partially influenced by a political movement advocating tolerance. Over the years, the enforcement approach has progressively become more lenient. As of 2021, cannabis use has been fully decriminalized, with it being treated as an administrative infraction primarily when used in highly visible public places. There is a possibility that cannabis may be legalized for recreational use by adults aged 21 and older in the future, with regulations akin to those for alcohol. Public and cross-party political support for the complete decriminalization of cannabis increased in the 2010s with increasing usage for both medical and recreational purposes, and the establishment of a political party primarily devoted to this cause; on July 19, 2018, the Knesset approved a bill for decriminalization, although the supporters of recreational cannabis use insisted that this did not represent complete decriminalization. The law came into effect on April 1, 2019. On June 25, 2020, further legislation designed to decriminalize possession of up to 50 grams of cannabis began its passage through the Knesset.

Medical cannabis research includes any medical research on using cannabis. Different countries conduct and respond to medical cannabis research in different ways.

D. Darryl Hudson is a Canadian scientist, inventor, serial entrepreneur and musician. Hudson was awarded the Alexander Graham Bell Canada graduate scholarship and the first MITACS Industrial post-doctoral fellowship award and received his PhD in molecular biology and genetics from Guelph University in 2010 specializing in genetic engineering of crop plants. Dr. Hudson performs studies and clinical research on psilocybin, and is the co-founder of GoodCap Pharmaceuticals, a psychedelic pharmaceutical company based in Canada.

<span class="mw-page-title-main">Psilocybin therapy</span> Experimental use of psilocybin to treat anxiety & depression

Psilocybin therapy is the use of psilocybin in treating a range of mental health conditions, such as depression, anxiety, addictions, obsessive compulsive disorder, and psychosis. It is one of several forms of psychedelic therapy under study. Psilocybin was popularized as a psychedelic recreational drug in the 1970s and was classified as a Schedule I drug by the DEA. Research on psilocybin as a medical treatment was restricted until the 1990s because of the sociocultural fear of dependence on this drug. As of 2022, psilocybin is the most commonly researched psychedelic due to its safety and low potential for abuse and dependence. Clinical trials are being conducted at universities and there is evidence confirming the use of psilocybin in the treatment of depression, PTSD and end of life anxiety.

<span class="mw-page-title-main">Psilocybin decriminalization in the United States</span> Movement to decriminalize psilocybin in the United States

The movement to decriminalize psilocybin in the United States began in 2019 with Denver, Colorado, becoming the first city to decriminalize psilocybin in May of that year. The cities of Oakland and Santa Cruz, California, decriminalized psilocybin in June 2019 and January 2020, respectively. Washington, D.C., followed soon in November 2020, as did Somerville, Massachusetts, in January 2021, and then the neighboring Cambridge and Northampton in February 2021 and March 2021, respectively. Seattle, Washington, became the largest U.S. city on the growing list in October 2021. Detroit, Michigan, followed in November 2021.

<span class="mw-page-title-main">MindMed</span> Psychedelic medicine biotech company

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.

Heroic Hearts Project is a registered 501(c)(3) nonprofit organization, functioning as a support group for US military veterans. The project engages psychedelic therapy to help people suffering a range of psychological maladies, such as PTSD, MST, severe depression, anxiety, etс. The organization has also been instrumental in the ongoing movement to change state and federal drug policies and overcome the stigma around them.

References

  1. ↑ Halper, Evan (1 July 2014). "Pot researcher abruptly fired by University of Arizona". Los Angeles Times. Retrieved 9 August 2014.
  2. ↑ Kovaleski, Serge F. (9 August 2014). "Medical Marijuana Research Hits Wall of U.S. Law". New York Times. Retrieved 9 August 2014.
  3. 1 2 3 Young, Saundra (14 July 2014). "Medical marijuana research stalls after Arizona professor is let go". CNN. Retrieved 9 August 2014.
  4. ↑ "Scottsdale Research Institute".
  5. 1 2 Hausfeld, Russell (23 March 2023). "Who's Researching the Researchers?". Truth Dig. Retrieved 5 June 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.